Kelix Bio Is A Specialty Generic Pharmaceuticals Company Dedicated To Improving Access To Critical Care And Oncology Medications In Emerging Marketsparticularly In Africaestablished In 2020 Through A Merger Between An Egyptian Pharmaceuticals Manufacturer And An Indian Generic Drugs Companykelix Bio Operates As A Pan African Biopharmaceutical Platformthe Company Is Supported By Development Partners Internationalbritish International Investmentand The European Bank For Reconstruction And Development Kelix Bio Focuses On Providing Specialty Generics At Affordable Pricesoffering Products That Are Typically 5Lower In Cost Than Those Of Competitor Innovator Companiesthe Company Supplies Its Medications To 46 Countriesincluding 20 African Nationsthrough Hospitals And Clinicskelix Bio Aims To Address Healthcare Gaps In Underserved Markets By Emphasizing Cost Efficiency And Reliable Supply Chainsallowing Customers To Spend Less On Medications Compared To The Average In Africa
